SUN Lei,LAN Xiu,LYU Zhuqing, et al. The role of Schisandrin B in inhibiting proliferation of gefitinib-resistant lung cancer cells via down-regulation of IGFBP2 expression[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2021, 51(4): 311-314,318.
Abstract：Objective: To investigate the role of Schisandrin B (Sch B) in inhibiting proliferation of gefitinib (Gef) resistant lung cancer cells and its molecular mechanism. Methods: PC9/GR (Gefitinib resistant PC9 cells) resistant cells were domesticated with gradient concentration of Gef and maintained with 200 mmol/L Gef. The difference of IGFBP2 expression and the viability between PC9 and PC9/GR cells were analyzed. The viability, apoptosis, IGFBP2 expression and phosphorylation of AKT and mTORC1were measured with and without Sch B treatment. Lentivirus transfection to obtain IGFBP2 overexpression (OE) cells was applied to confirm the role of IGFBP2 on proliferation inhibition of Sch B in PC9/GR cells. Results: The expression of IGFBP2 in PC9/GR cells was higher than that in PC9 cells (P<0.05). After Sch B treatment, the survival rate, IGFBP2 expression and phosphorylation of AKT and mTORC1 decreased (P<0.05), whereas the apoptosis increased (P<0.05). The overexpression of IGFBP2 increased the phosphorylation of AKT and mTORC1 but alleviated the proliferation inhibition of Sch B in PC9/GR cells (P<0.05). Conclusion: Sch B induces proliferation inhibition via down-regulating expression of IGFBP2 in PC9/GR cells.
参考文献：
[1] AGGARWAL A, LEWISON G, IDIR S, et al. The state of lung cancer research: a global analysis[J]. J Thorac Oncol, 2016, 11(7): 1040-1050.
[2] JACKMAN D, PAO W, RIELY G J, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer[J]. J Clin Oncol, 2010, 28(2): 357-360.
[3] NASSER M I, ZHU S, CHEN C, et al. A comprehensive review on Schisandrin B and its biological properties[J]. Oxid Med Cell Longev, 2020, 2020: 2172740.
[4] LV X, ZHAO L, HAO Y, et al. Schisandrin B inhibits the proliferation of human lung adenocarcinoma A549 cells by inducing cycle arrest and apoptosis[J]. Int J Clin Exp Med, 2015, 8(5): 6926-6936.
[5] YAN C, GAO L, QIU X, et al. Schisandrin B synergizes docetaxel-induced restriction of growth and invasion of cervical cancer cells in vitro and in vivo[J]. Ann Transl Med, 2020, 8(18): 1157.
[6] HUANG M, JIN J, SUN H, et al. Reversal of Pglycoprotein- mediated multidrug resistance of cancer cells by five schizandrins isolated from the Chinese herb Fructus Schizandrae[J]. Cancer Chemother Pharmacol, 2008, 62(6): 1015-1026.
[7] WANG S, WANG A, SHAO M, et al. Schisandrin B reverses doxorubicin resistance through inhibiting P-glycoprotein and promoting proteasome-mediated degradation of survivin[J]. Sci Rep, 2017, 7(1): 8419.
[8] LU H, WANG L, GAO W, et al. IGFBP2/FAK pathway is causally associated with dasatinib resistance in non-small cell lung cancer cells[J]. Mol Cancer Ther, 2013, 12(12): 2864-2873.
[9] WANG F, ZHANG L, SAI B, et al. BMSC-derived leptin and IGFBP2 promote erlotinib resistance in lung adenocarcinoma cells through IGF-1R activation in hypoxic environment[J]. Cancer Biol Ther, 2020, 21(1): 61-71.
[10] NAGANO T, TACHIHARA M, NISHIMURA Y. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy[J]. Cells, 2018, 7(11): 212.
[11] PARK J H, CHOI Y J, KIM S Y, et al. Activation of the IGF1R pathway potentially mediates acquired resistance to mutant-selective 3rd-generation EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer[J]. Oncotarget, 2016, 7(16): 22005-22015.
[12] LIU Y, LI F, YANG Y T, et al. IGFBP2 promotes vasculogenic mimicry formation via regulating CD144 and MMP2 expression in glioma[J]. Oncogene, 2019, 38(11): 1815-1831.
